Addressing Confounding and Continuous Exposure Measurement Error Using Corrected Score Functions

Brian Richardson



Department of Biostatistics, University of North Carolina at Chapel Hill

August 5, 2025

Scan for slides

August 5, 2025

Acknowledgements

Bryan Blette, PhD



Vanderbilt University

Peter Gilbert, PhD



University of Washington Medical Center

Michael Hudgens, PhD



UNC Chapel Hill

This research was supported by the U.S. Public Health Service Grant Al068635, the National Institute of Allergy And Infectious Diseases of the National Institutes

of Health (NIH) under Award Number R37 Al054165, and the National Institute of Environmental Health Sciences of the NIH under Award Number T32

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

NOVEMBER 28, 2013

VOL. 369 NO. 22

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

Scott M. Hammer, M.D., Magdalena E. Sobiesszczyk, M.D., M.P.H., Foldy Janes, Ph.D., Shelly T. Karuna, M.D., Mark Jr., Mulligan, M.D., Doug Grove, M.S., Ben Y. A Kollin, Ph.D., Sussan P. Buchbinder, M.D., Michael C. Keefer, M.D., Georgia D. Tomaras, Ph.D., Nicole Frahm, Ph.D., John Hural, Ph.D., Chuka Anude, M.D., Ph.D., Barry S. Graham, M.D., Ph.D., Mary E. Farama, M.A., P.A.-C., Elizabeth Adams, M.D., Edwin DeJesus, M.D., Richard M. Novak, M.D., lan Frank, M.D., Carter Bentley, Ph.D., Shelly Ramirez, M.A., Rong Fiu, M.S., Richard A. Koup, M.D., John R. Mascold, M.D., Cary, J. Nebel, M.D., Ph.D., Jawrence Corey, M.D., and Peter B. Gilbert, Ph.D., James Kublin, M.D., M.P.H., M. Juliana McElrath, M.D., Ph.D., Lawrence Corey, M.D., and Peter B. Gilbert, Ph.D., for the HVTM YOS Study Teams.

• HVTN 505 trial: trial of a preventive HIV vaccine



ESTABLISHED IN 1812

NOVEMBER 28, 2013

VOL. 369 NO. 22

Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

Scott M. Hammer, M.D., Magdalena E. Sobiesszczyk, M.D., M.P.H., Holly Janes, Ph.D., Shelly T. Karuna, M.D., Mark, M., Mulligan, M.D., Doug Grove, M.S., Bey N.A. Kollin, Ph.D., Susan P. Buchbinder, M.D., Michael C. Keefer, M.D., Georgia D. Tomaras, Ph.D., Nicole Frahm, Ph.D., John Hural, Ph.D., Chuka Anude, M.D., Ph.D., Barry S. Graham, M.D., Ph.D., Mary E. Enram, M.A., P.A.C., Elizabeth Adams, M.D., Edwin DeJesus, M.D., Richard M. Novak, M.D., Lan Frank, M.D., Carder Bentley, Ph.D., Shelly Ramirez, M.A., Rong Fis, M.S., Richard A. Koup, M.D., John R. Massodi, M.D., Cardy, J. Mabel, M.D., Ph.D., David C. Montefiori, Ph.D., James Kublin, M.D., M.P.H., M., Juliana McElrath, M.D., Ph.D., Lawrence Corey, M.D., and Peter B. Gilbert, Ph.D., for the Hurt Vis OS Study Teams.

- HVTN 505 trial: trial of a preventive HIV vaccine
- stopped early after reaching predetermined cutoffs for efficacy futility [2]







Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Holly F. Janes J Kristen W. Cohen J Nicole Frahm J Stechen C. De Rosa J Brittany Sanchez J John Hural J Crain A. Magazet J Shelly Karuna, Carter Bentley, Raphael Gottardo, Greg Finak, Douglas Grove, Mingchao Shen, Barney S. Graham, Richard A. Koup, Mark J. Mulligan, Beryl Koblin, Susan P. Buchbinder, Michael C. Keefer, Elizabeth Adams, Chuka Anude, A Lawrence Corev. Mandalena Sohieszczyk 11 Scott M. Hammer 11 Peter R. Gilbert 1 and M. Juliana McFlrath

• several possible biomarker correlates of HIV among vaccine recipients [3, 1, 4]





Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Holly F. Janes J Kristen W. Cohen J Nicole Frahm J Stechen C. De Rosa J Brittany Sanchez J John Hural J Crain A. Magazet J Shelly Karuna, Carter Bentley, Raphael Gottardo, Greg Finak, Douglas Grovo, Mingchao Shen, Barney S. Graham, Richard A. Koup. Mark J. Mulligan, Beryl Koblin, Susan P. Buchbinder, Michael C. Keefer, Elizabeth Adams, Chuka Anude, A Lawrence Corev. Mandalena Sohieszczyk 11 Scott M. Hammer 11 Peter R. Gilbert 1 and M. Juliana McFlrath

- several possible biomarker correlates of HIV among vaccine recipients [3, 1, 4]
- of interest to assess the effect of these biomarkers on risk of HIV acquisition

Brian Richardson







Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Holly F. Janes J Kristen W. Cohen J Nicole Frahm J Stephen C. De Rosa J Brittany Sanchez J John Hural J Craig A. Magaret J Shelly Karuna, Carter Bentley, Raphael Gottardo, Greg Finak, Douglas Grovo, Mingchao Shen, Barney S. Graham, Richard A. Koup. Mark J. Mulligan, Bervi Koblin, Susan P. Buchbinder, Michael C. Keefer, Elizabeth Adams, Chuka Anude, Lawrence Corev. Mandalena Sohieszczyk 11 Scott M. Hammer 11 Peter R. Gilbert 1 and M. Juliana McFlrath

- several possible biomarker correlates of HIV among vaccine recipients [3, 1, 4]
- of interest to assess the effect of these biomarkers on risk of HIV acquisition
- biomarker-HIV relationship is confounded







Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Holly F., Janes, 1 Kristen W. Cohen, 1 Nicole Frahm, 1 Stephen C. De Rosa, 1 Brittany Sanchez, 1 John Hural, 1 Craig A. Magaret, 1 Shelly Karuna, Carter Bentley, Raphael Gottardo, Greg Finak, Douglas Grovo, Mingchao Shen, Barney S. Graham, Richard A. Koup. Mark J. Mulligan, Bervi Koblin, Susan P. Buchbinder, Michael C. Keefer, Elizabeth Adams, Chuka Anude, Lawrence Corev. Mandalena Sohieszczyk 11 Scott M. Hammer 11 Peter R. Gilbert 1 and M. Juliana McFlrath

- several possible biomarker correlates of HIV among vaccine recipients [3, 1, 4]
- of interest to assess the effect of these biomarkers on risk of HIV acquisition
- biomarker-HIV relationship is confounded
- biomarkers are measured with error

Goal

To estimate the causal effect of a continuous exposure on an outcome when

Goal

To estimate the **causal effect** of a continuous exposure on an outcome when


(i) the exposure-outcome relationship is potentially confounded

Goal

To estimate the **causal effect** of a continuous exposure on an outcome when

- (i) the exposure-outcome relationship is potentially confounded
- (ii) the exposure is measured with error






$$\underbrace{\mathbf{a}}_{\text{biomarker}} \Rightarrow \underbrace{Y(\mathbf{a})}_{\text{potential HIV status if biomarker } \mathbf{a}} \Rightarrow \underbrace{\mathbb{E}\{Y(\mathbf{a})\}}_{\text{HIV risk if } \mathbf{a}}$$


"What would be the risk of HIV if, possibly counter to fact, somebody were to have biomarker level **a**?"


$$\underbrace{\mathbf{a}}_{\text{biomarker}} \Rightarrow \underbrace{Y(\mathbf{a})}_{\text{potential HIV status if biomarker } \mathbf{a}} \Rightarrow \underbrace{\mathbb{E}\{Y(\mathbf{a})\}}_{\text{HIV risk if } \mathbf{a}}$$

Estimand (dose-response surface): $\eta(a) \equiv E[Y(a)]$ for $a \in A$









- G-Formula (GF)
- Inverse Probability Weighting (IPW)
- Doubly Robust Methods (DR)

- G-Formula (GF)
 - ▶ Fit an outcome regression model for $\mu(L, A; \beta) \equiv E(Y|L, A)$.
 - ▶ Marginalize over the distribution of confounders: $\widehat{\eta}(\mathbf{a}) = n^{-1} \sum_{i=1}^{n} \mu(\mathbf{L}_i, \mathbf{a}; \widehat{\boldsymbol{\beta}})$.
- Inverse Probability Weighting (IPW)
- Doubly Robust Methods (DR)

- G-Formula (GF)
- Inverse Probability Weighting (IPW)
 - Fit a **propensity model** for the distribution of A|L.
 - Weight each observation based on its propensity score.
 - ▶ Fit a regression model for *Y* on *A* using weighted observations.
- Doubly Robust Methods (DR)

- G-Formula (GF)
- Inverse Probability Weighting (IPW)
- Doubly Robust Methods (DR)
 - Fit a propensity model for A given L.
 - Weight each observation based on its propensity score.
 - Fit an outcome regression model for $\mu(L, A; \beta) \equiv E(Y|L, A)$ using weighted observations.
 - ▶ Marginalize over the distribution of confounders: $\widehat{\eta}(\mathbf{a}) = n^{-1} \sum_{i=1}^{n} \mu(\mathbf{L}_i, \mathbf{a}; \widehat{\boldsymbol{\beta}})$.



Estimating Function: a function of the observed data and the parameter of interest

Estimating Function: a function of the observed data and the parameter of interest

$$\underbrace{\Psi}_{\text{est. fun.}} \left(\underbrace{Y, L, A}_{\text{data}} ; \right)$$

Estimating Function: a function of the observed data and the parameter of interest

$$\underbrace{\Psi}_{\text{est. fun.}} \left(\underbrace{Y, L, A}_{\text{data}} ; \underbrace{\theta}_{\text{param.}} \right)$$

Estimating Function: a function of the observed data and the parameter of interest

est. fun.
$$(Y, L, A; \theta)$$
 param.

that is unbiased, meaning

Estimating Function: a function of the observed data and the parameter of interest

$$\underbrace{\Psi}_{\text{est. fun.}} \left(\underbrace{Y, L, A}_{\text{data}} ; \underbrace{\theta}_{\text{param.}} \right)$$

that is unbiased, meaning

$$\mathsf{E}\{\Psi(Y, L, A; \underbrace{\theta_0}_{\mathsf{true}})\} = \mathbf{0}.$$

• Given an estimating function Ψ and observed data $\{(Y_i, L_i, A_i) : i = 1, ..., n\}$, we can find an estimator $\hat{\theta}$ as the solution to

• Given an estimating function Ψ and observed data $\{(Y_i, L_i, A_i) : i = 1, ..., n\}$, we can find an estimator $\hat{\theta}$ as the solution to

$$\sum_{i=1}^{n} \Psi(\underbrace{Y_i, L_i, A_i}_{\text{observed}}; \boldsymbol{\theta}) = \mathbf{0}.$$

• Given an estimating function Ψ and observed data $\{(Y_i, L_i, A_i) : i = 1, ..., n\}$, we can find an estimator $\hat{\theta}$ as the solution to

$$\sum_{i=1}^{n} \Psi(\underbrace{Y_{i}, L_{i}, A_{i}}_{\text{observed}}; \theta) = \mathbf{0}.$$


 $oldsymbol{\widehat{ heta}}$ is consistent and asymptotically normal and has a simple variance estimator [6].

• Given an estimating function Ψ and observed data $\{(Y_i, L_i, A_i) : i = 1, ..., n\}$, we can find an estimator $\hat{\theta}$ as the solution to

$$\sum_{i=1}^{n} \Psi(\underbrace{Y_i, L_i, A_i}_{\text{observed}}; \theta) = \mathbf{0}.$$

- $oldsymbol{\hat{ heta}}$ is consistent and asymptotically normal and has a simple variance estimator [6].
- The G-formula, IPW, and DR estimators are all solutions to estimating equations with functions Ψ_{GF} , Ψ_{IPW} , Ψ_{DR} .

Measurement Error



Addressing Confounding and Measurement Error

Can we just substitute A^* for A and find the solution to

$$\sum_{i=1}^{n} \Psi(Y_i, \mathbf{L}_i, \underbrace{\mathbf{A}_i^*}_{\text{mismeasured}}; \boldsymbol{\theta}) = \mathbf{0}?$$

Addressing Confounding and Measurement Error

Can we just substitute A^* for A and find the solution to

$$\sum_{i=1}^{n} \Psi(Y_i, L_i, \underbrace{A_i^*}_{\text{mismeasured}}; \theta) = \mathbf{0}?$$

No! This leads to bias in $\widehat{\boldsymbol{\theta}}$ because

$$\mathsf{E}\{\Psi(Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}_0)\} \neq \mathbf{0}.$$

Addressing Confounding and Measurement Error

Can we just substitute A^* for A and find the solution to

$$\sum_{i=1}^{n} \Psi(Y_i, \mathbf{L}_i, \underbrace{\mathbf{A}_i^*}_{\text{mismeasured}}; \boldsymbol{\theta}) = \mathbf{0}?$$

No! This leads to bias in $\widehat{\boldsymbol{\theta}}$ because

$$\mathsf{E}\{\boldsymbol{\Psi}(Y,\boldsymbol{L},\boldsymbol{A}^*;\boldsymbol{\theta}_0)\}\neq\boldsymbol{0}.$$

We need a new estimating function $\widetilde{\Psi}$ such that

$$\mathsf{E}\{\underbrace{\widetilde{oldsymbol{\psi}}}_{\mathsf{new}\;\mathsf{est.}\;\mathsf{fun.}}(Y,oldsymbol{L},\underbrace{oldsymbol{\mathcal{A}}^*}_{\mathsf{mismeasured}};oldsymbol{ heta}_0)\}=oldsymbol{0}.$$

Given the "oracle" estimating function Ψ , the "corrected score" function Ψ_{CS} can be created following Novick and Stefanski [5]:

1 add additional *imaginary* measurement error to the mismeasured exposure:

$$\widetilde{\pmb{A}}=\pmb{A}^*+\imath\widetilde{\pmb{\epsilon}}.$$

- **1** add additional *imaginary* measurement error to the mismeasured exposure:
 - $\widetilde{\pmb{A}} = \pmb{A}^* + i\widetilde{\pmb{\epsilon}}.$
- ② Plug \widetilde{A} into Ψ , and keep only the real part of the complex-valued function.

- **1** add additional *imaginary* measurement error to the mismeasured exposure:
 - $\widetilde{\mathbf{A}} = \mathbf{A}^* + i\widetilde{\boldsymbol{\epsilon}}.$
- ② Plug $\widetilde{\mathbf{A}}$ into $\mathbf{\Psi}$, and keep only the real part of the complex-valued function.
- ullet Take the expectation over the additional measurement error $\widetilde{\epsilon}$.

- **1** add additional *imaginary* measurement error to the mismeasured exposure:
 - $\widetilde{\mathbf{A}} = \mathbf{A}^* + i\widetilde{\mathbf{\epsilon}}.$
- ② Plug $\widetilde{\mathbf{A}}$ into $\mathbf{\Psi}$, and keep only the real part of the complex-valued function.
- ullet Take the expectation over the additional measurement error $\widetilde{\epsilon}.$

$$oldsymbol{\Psi}_{CS}\left(Y, oldsymbol{L}, oldsymbol{A}^*; oldsymbol{ heta}
ight) = \mathsf{E}\left[\mathsf{Re}\left\{oldsymbol{\Psi}_0(Y, oldsymbol{L}, \widetilde{oldsymbol{A}}; oldsymbol{ heta})
ight\} | Y, oldsymbol{L}, oldsymbol{A}^*
ight]$$



Corrected Score Functions (contd)

Under certain conditions, the corrected score function Ψ_{CS} is then unbiased, meaning

$$\mathsf{E}\{\Psi_{\mathit{CS}}(Y, L, \underbrace{A^*}_{\mathsf{mismeasured}}; \theta_0)\} = \mathbf{0}.$$

Corrected Score Functions (contd)

Under certain conditions, the corrected score function Ψ_{CS} is then unbiased, meaning

$$\mathsf{E}\{\Psi_{\mathit{CS}}(Y, L, \underbrace{A^*}_{\mathsf{mismeasured}}; \theta_0)\} = \mathbf{0}.$$

The G-Formula, IPW, and DR estimating functions all satisfy these conditions, and so can be "corrected."

$$egin{aligned} oldsymbol{\Psi}_{GF} &\longrightarrow oldsymbol{\Psi}_{CS-GF} \ oldsymbol{\Psi}_{IPW} &\longrightarrow oldsymbol{\Psi}_{CS-IPW} \ oldsymbol{\Psi}_{DR} &\longrightarrow oldsymbol{\Psi}_{CS-DR} \end{aligned}$$

Brian Richardson

• Sometimes we can find a closed-form algebraic expression for

$$\Psi_{CS}(Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}) = \underbrace{\mathbb{E}\left[\operatorname{Re}\left\{\Psi_0(Y, \boldsymbol{L}, \boldsymbol{A}^* + i\widetilde{\boldsymbol{\epsilon}}; \boldsymbol{\theta})\right\} \middle| Y, \boldsymbol{L}, \boldsymbol{A}^*\right]}_{\mathbb{E}\left\{f(\widetilde{\boldsymbol{\epsilon}})\right\}}.$$

• Sometimes we can find a closed-form algebraic expression for

$$\Psi_{CS}\left(Y, \boldsymbol{L}, \boldsymbol{A}^{*}; \boldsymbol{\theta}\right) = \underbrace{\mathbb{E}\left[\operatorname{Re}\left\{\Psi_{0}(Y, \boldsymbol{L}, \boldsymbol{A}^{*} + i\widetilde{\boldsymbol{\epsilon}}; \boldsymbol{\theta}\right)\right\} | Y, \boldsymbol{L}, \boldsymbol{A}^{*}\right]}_{\mathbb{E}\left\{f\left(\widetilde{\boldsymbol{\epsilon}}\right)\right\}}.$$

• Alternatively, we can approximate this expectation with Monte Carlo replicates

• Sometimes we can find a closed-form algebraic expression for

$$\Psi_{CS}(Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}) = \underbrace{\mathbb{E}\left[\operatorname{Re}\left\{\Psi_0(Y, \boldsymbol{L}, \boldsymbol{A}^* + i\widetilde{\boldsymbol{\epsilon}}; \boldsymbol{\theta})\right\} \middle| Y, \boldsymbol{L}, \boldsymbol{A}^*\right]}_{\mathbb{E}\left\{f(\widetilde{\boldsymbol{\epsilon}})\right\}}.$$

• Alternatively, we can approximate this expectation with Monte Carlo replicates

$$\mathsf{E}\{f(\widetilde{\epsilon})\} pprox B^{-1} \sum_{b=1}^{B} f(\widetilde{\epsilon}_b)$$

• Sometimes we can find a closed-form algebraic expression for

$$\Psi_{CS}(Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}) = \underbrace{\mathbb{E}\left[\operatorname{Re}\left\{\Psi_0(Y, \boldsymbol{L}, \boldsymbol{A}^* + i\widetilde{\boldsymbol{\epsilon}}; \boldsymbol{\theta})\right\} | Y, \boldsymbol{L}, \boldsymbol{A}^*\right]}_{\mathbb{E}\left\{f(\widetilde{\boldsymbol{\epsilon}})\right\}}.$$

• Alternatively, we can approximate this expectation with Monte Carlo replicates

$$\mathsf{E}\{f(\widetilde{\epsilon})\} pprox B^{-1} \sum_{b=1}^{B} f(\widetilde{\epsilon}_b)$$


$$\Longrightarrow \Psi^B_{MCCS}(Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}) = B^{-1} \sum_{b=1}^B \operatorname{Re} \left\{ \Psi_0(Y, \boldsymbol{L}, \boldsymbol{A}^* + i \widetilde{\boldsymbol{\epsilon}}_b; \boldsymbol{\theta}) \right\}$$




Simulation Setting

- confounder $L \sim \mathcal{N}(0, 0.36)$
- exposure $\mathbf{A} = (A_1, A_2)$ with $\mathbf{A}|L \sim \mathcal{N}_2(\mathbf{0}, \mathbf{I})$
- exposure measurement error $\epsilon \sim \mathcal{N}_2(\mathbf{0}, \sigma_{me}^2 \mathbf{I})$
- outcome Y with $Y|L, \mathbf{A} \sim \mathcal{N}(A_1 + A_2 + L, 1)$
- implied MSM of $\eta(\boldsymbol{a};\boldsymbol{\gamma})=\gamma_0+\gamma_1a_1+\gamma_2a_2$ for $\boldsymbol{\gamma}=(\gamma_0,\gamma_1,\gamma_2)=(0,1,1)$
- sample size n = 800

Simulation Results: Estimator



Simulation Results: Confidence Interval




Application: HVTN 505 Trial


- two exposures (both log-transformed):
 - (i) antibody-dependent cellular phagocytosis (ADCP)
 - (ii) recruitment of Fc γ RIIa of the H131-Con S gp140 protein (RII)
- case-cohort sampling: immunologic markers only measured in stratified random sample of controls
- covariates: age, race, BMI, behavior risk, CD4-P, and CD8-P
- two analyses:
 - (i) DR estimator with a log-linear outcome model
 - (ii) g-formula with a log-quadratic outcome model



Application: DR Method with Linear Outcome Model



Application: G-Formula with Quadratic Outcome Model



Mismex: Causal Inference for Mismeasured Exposures



Paper in Biometrics





GitHub R package

References

- [1] Youyi Fong, Xiaoying Shen, Vicki C Ashley, Aaron Deal, Kelly E Seaton, Chenchen Yu, Shannon P Grant, Guido Ferrari, Allan C deCamp, Robert T Bailer, et al. Modification of the association between T-cell immune responses and human immunodeficiency virus type 1 infection risk by vaccine-induced antibody responses in the HVTN 505 trial. *The Journal of Infectious Diseases*, 217(8):1280–1288, 2018.
- [2] Scott M Hammer, Magdalena E Sobieszczyk, Holly Janes, Shelly T Karuna, Mark J Mulligan, Doug Grove, Beryl A Koblin, Susan P Buchbinder, Michael C Keefer, Georgia D Tomaras, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. New England Journal of Medicine, 369(22):2083–2092, 2013.
- [3] Holly E Janes, Kristen W Cohen, Nicole Frahm, Stephen C De Rosa, Brittany Sanchez, John Hural, Craig A Magaret, Shelly Karuna, Carter Bentley, Raphael Gottardo, et al. Higher T-cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.

 The Journal of Infectious Diseases, 215(9):1376–1385, 2017.
- [4] Scott D Neidich, Youyi Fong, Shuying S Li, Daniel E Geraghty, Brian D Williamson, William Chad Young, Derrick Goodman, Kelly E Seaton, Xiaoying Shen, Sheetal Sawant, et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. *Journal of Clinical Investigation*, 129(11):4838–4849, 2019.
- 5] Steven J Novick and Leonard A Stefanski. Corrected score estimation via complex variable simulation extrapolation. Journal of the American Statistical Association, 97(458):472–481, June 2002. ISSN 0162-1459, 1537-274X. doi: 10.1198/016214502760047005. URL http://www.tandfonline.com/doi/abs/10.1198/016214502760047005.
- [6] Leonard A Stefanski and Dennis D Boos. The calculus of M-estimation. The American Statistician, 56(1):29-38, 2002.

Appendix

Appendix: Notation

- true exposure: $\mathbf{A} = (A_1, \dots, A_m)$
- measured exposure: $\mathbf{A}^* = (A_1^*, \dots, A_m^*) = \mathbf{A} + \epsilon$
- ullet measurement error: $oldsymbol{\epsilon}$
- potential outcome: Y(a)
- observed outcome: Y
- confounders: $L = (L_1, L_2, ..., L_p)$

Observe: iid copies of (Y_i, L_i, A_i^*) .

Estimand: dose-response curve $\eta(\mathbf{a}) \equiv E[Y(\mathbf{a})]$ for $\mathbf{a} \in \mathcal{A}$.



Appendix: Assumptions

- (i) causal consistency: Y = Y(a) when A = a
- (ii) conditional exchangeability: $Y(a) \perp \!\!\! \perp A|L$ for all $a \in A$
- (iii) **positivity**: $f_{A|L}(a|I) > 0$ for all I such that $f_L(I) > 0$ and for all $a \in A$
- (iv) independent measurement error: $\epsilon \perp \!\!\! \perp (Y, L, A)$
- (v) classical additive measurement error: $\epsilon \sim \mathcal{N}_{\it m}(0, \mathbf{\Sigma}_{\it me})$

Appendix: G-Formula

- fit the outcome model $\mu(L, A; \beta) \equiv E(Y|L, A)$
- estimate the dose-response curve by marginalizing over the distribution of confounders: $\widehat{\eta}(\mathbf{a}) = n^{-1} \sum_{i=1}^{n} \mu(\mathbf{L}_i, \mathbf{a}; \widehat{\boldsymbol{\beta}})$
- This can be expressed as an M-estimator with estimating function

$$\Psi_{0-GF}(Y, \boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\theta}_{GF}) = \begin{bmatrix} \{Y - \mu(\boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\beta})\} \, \partial_{\boldsymbol{\beta}} \mu(\boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\beta}) \\ \eta(\boldsymbol{a}) - \mu(\boldsymbol{L}, \boldsymbol{a}; \boldsymbol{\beta}) \end{bmatrix}$$

Appendix: IPW

obtain/estimate standardized propensity score weights

$$SW(\boldsymbol{L}, \boldsymbol{A}) = \frac{f_{\boldsymbol{A}}(\boldsymbol{A})}{f_{\boldsymbol{A}|\boldsymbol{L}}(\boldsymbol{A}|\boldsymbol{L})}$$

- use weighted observations to estimate the dose-response curve $\eta(\mathbf{a}; \gamma)$
- This can be expressed as an M-estimator with estimating function

$$\Psi_{0-IPW}(Y, \boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\theta}_{IPW}) = \begin{bmatrix} \Psi_{PS}(\boldsymbol{L}, \boldsymbol{A}) \\ SW(\boldsymbol{L}, \boldsymbol{A}) \{Y - \eta(\boldsymbol{A}; \boldsymbol{\gamma})\} \partial_{\boldsymbol{\gamma}} \eta(\boldsymbol{A}; \boldsymbol{\gamma}) \end{bmatrix}$$

Appendix: DR

- obtain/estimate standardized propensity score weights SW(L, A)
- use weighted observations to estimate the **outcome model** $\mu(L, A; \beta) \equiv \mathsf{E}(Y|L, A)$
- estimate the dose-response curve by marginalizing over the distribution of confounders
- This can be expressed as an M-estimator with estimating function

$$\Psi_{0-DR}(Y, \boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\theta}_{DR}) = \begin{bmatrix} \Psi_{PS}(\boldsymbol{L}, \boldsymbol{A}) \\ SW(\boldsymbol{L}, \boldsymbol{A}) \{ Y - \mu(\boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\beta}) \} \partial_{\boldsymbol{\beta}} \mu(\boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\beta}) \end{bmatrix} \eta(\boldsymbol{a}) - \mu(\boldsymbol{L}, \boldsymbol{a}; \boldsymbol{\beta})$$

• doubly robust* to models for $\mu(\mathbf{L}, \mathbf{A}; \boldsymbol{\beta})$ and $f_{\mathbf{A}|\mathbf{L}}(\mathbf{A}|\mathbf{L})$.



Appendix: Corrected Score Functions

• Suppose the oracle estimating function is conditionally unbiased, meaning

$$\mathsf{E}\{\Psi_0(Y,\boldsymbol{L},\boldsymbol{A};\boldsymbol{\theta})|\boldsymbol{A}\}=\mathbf{0}.$$

Define the corrected score function as

$$oldsymbol{\Psi}_{CS}\left(Y, oldsymbol{L}, oldsymbol{A}^*; oldsymbol{ heta}
ight) = \mathsf{E}\left[\mathsf{Re}\left\{oldsymbol{\Psi}_0(Y, oldsymbol{L}, \widetilde{oldsymbol{A}}; oldsymbol{ heta})
ight\} | Y, oldsymbol{L}, oldsymbol{A}^*
ight],$$

where $\widetilde{\mathbf{A}} = \mathbf{A}^* + i\widetilde{\epsilon}$, $i = \sqrt{-1}$, Re(·) denotes the real component of a complex number, and $\widetilde{\epsilon} \sim \mathcal{N}(\mathbf{0}, \mathbf{\Sigma}_{me})$.

Then

$$E \{ \Psi_{CS} (Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}) | Y, \boldsymbol{L}, \boldsymbol{A} \} = \Psi_0 (Y, \boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\theta})$$

$$\implies E [E \{ \Psi_{CS} (Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}) | Y, \boldsymbol{L}, \boldsymbol{A} \}] = E \{ \Psi_0 (Y, \boldsymbol{L}, \boldsymbol{A}; \boldsymbol{\theta}) \}$$

$$\implies E \{ \Psi_{CS} (Y, \boldsymbol{L}, \boldsymbol{A}^*; \boldsymbol{\theta}) \} = \mathbf{0}$$